Multiple sclerosis and related disorders · 2024
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balshi Alexandra, Leuenberger Grace, Dempsey John, Baber Ursela, Sloane Jacob A
Аннотация
BACKGROUND: While glucagon-like peptide-1 agonist medications (GLP-1s) are on the rise, their safety and efficacy have not been studied in people with MS (PwMS).
OBJECTIVE: To investigate any adverse effects of GLP-1 medications in the MS population as well as their effectiveness for weight loss and vitamin D augmentation.
METHODS: We retrospectively identified PwMS who utilized a GLP-1 medication from 2006 to 2024. Wilcoxon signed rank tests for paired samples were used to compare pre- and post-GLP-1 body mass index (BMI), expanded disability status scale (EDSS), timed 25-foot walk (25FTW), and mean vitamin D values. Additional safety outcomes assessed during GLP-1 treatment were deaths, hospitalizations, clinician-confirmed relapses, and new MRI activity.
RESULTS: Following GLP-1 initiation, PwMS had a decrease in BMI (mean % BMI loss 3.7, p = 0.001) and an increase in vitamin D values (mean increase of 8.1 ng/mL, p = 0.0002), while no change in EDSS or T25FW was seen. There were no hospitalizations or deaths after GLP-1 initiation.
CONCLUSION: GLP-1 medications are safe and effective in PwMS and can help augment vitamin D levels.
OBJECTIVE: To investigate any adverse effects of GLP-1 medications in the MS population as well as their effectiveness for weight loss and vitamin D augmentation.
METHODS: We retrospectively identified PwMS who utilized a GLP-1 medication from 2006 to 2024. Wilcoxon signed rank tests for paired samples were used to compare pre- and post-GLP-1 body mass index (BMI), expanded disability status scale (EDSS), timed 25-foot walk (25FTW), and mean vitamin D values. Additional safety outcomes assessed during GLP-1 treatment were deaths, hospitalizations, clinician-confirmed relapses, and new MRI activity.
RESULTS: Following GLP-1 initiation, PwMS had a decrease in BMI (mean % BMI loss 3.7, p = 0.001) and an increase in vitamin D values (mean increase of 8.1 ng/mL, p = 0.0002), while no change in EDSS or T25FW was seen. There were no hospitalizations or deaths after GLP-1 initiation.
CONCLUSION: GLP-1 medications are safe and effective in PwMS and can help augment vitamin D levels.